Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni, +24

The Lancet Infectious Diseases

Severe InfectionsHealth SciencesAntibioticsAntimicrobial SusceptibilityCarbapenem-resistant Gram-negative Bacteria +7

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar, +18

Clinical Infectious Diseases

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin, +65

Clinical Microbiology and Infection

Antimicrobial SusceptibilityHealth SciencesAntibioticsVitro SynergismBetter Clinical Outcomes +9

Characteristics of long-COVID among older adults: a cross-sectional study

Vered Daitch, Dana Yelin, Muhammad Awwad, +20

International Journal of Infectious Diseases

Risk Factors and Multidimensional Assessment of Long Coronavirus Disease Fatigue: A Nested Case-Control Study

Ili Margalit, Dana Yelin, Moshe Sagi, +19

Clinical Infectious Diseases

The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

Yael Dishon Benattar, Muna Omar, Oren Zusman, +7

Clinical Infectious Diseases

Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study

Oren Zusman, L. Farbman, Z. Tredler, +4

Clinical Microbiology and Infection

Cardiovascular DiseaseClinical EpidemiologyPharmacotherapyLogistic AnalysisPublic Health +6

Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria

Anders Kristoffersson, Viktor Rognås, Margreke J. E. Brill, +19

Clinical Microbiology and Infection

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility

Jonathan Lellouche, David A. Schwartz, N. Elmalech, +28

Clinical Microbiology and Infection

Colistin SusceptibilityPathogen DetectionVitek® 2Clinical GastroenterologyMicrobiology +7

Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms

Yaakov Dickstein, Jonathan Lellouche, David A. Schwartz, +19

Clinical Infectious Diseases